ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00115219
Recruitment Status : Completed
First Posted : June 22, 2005
Last Update Posted : May 30, 2013
Sponsor:
Information provided by (Responsible Party):
Amgen